Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (463) 463
Publication (93) 93
Newspaper Article (89) 89
Paper (79) 79
Book / eBook (28) 28
Patent (12) 12
Book Chapter (1) 1
Book Review (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (111) 111
experiment (85) 85
experimental results (83) 83
humans (82) 82
particle physics (81) 81
high energy physics - experiment (80) 80
physics - high energy physics - experiment (80) 80
cern lhc coll (78) 78
hep (77) 77
physics (77) 77
p p: colliding beams (72) 72
p p: scattering (72) 72
male (67) 67
female (61) 61
ex (58) 58
middle aged (45) 45
statistical (43) 43
aged (38) 38
high energy physics (37) 37
7000 gev-cms8000 gev-cms (34) 34
adult (34) 34
animals (32) 32
[phys.hexp]physics [physics]/high energy physics - experiment [hep-ex] (31) 31
research (30) 30
analysis (27) 27
hadron-hadron scattering (26) 26
lhc-b (25) 25
lhcb (23) 23
colliding beams [p p] (22) 22
scattering [p p] (22) 22
cp: violation (21) 21
mass spectrum: (21) 21
oncology (21) 21
[ phys.hexp ] physics [physics]/high energy physics - experiment [hep-ex] (20) 20
nuclear experiment (20) 20
particles and fields (19) 19
diagnosis (18) 18
to be checked by faculty (18) 18
infectious diseases (17) 17
medicine (17) 17
particle physics - experiment (17) 17
patients (17) 17
7000 gev-cms8000 gev-cms13000 gev-cms (16) 16
care and treatment (16) 16
hep-ex (16) 16
management (16) 16
mortality (16) 16
risk factors (16) 16
asymmetry: cp (15) 15
b physics (15) 15
cancer (15) 15
elementary particles and fields (15) 15
muon: pair production (15) 15
rats (15) 15
young adult (15) 15
abridged index medicus (14) 14
library approved (14) 14
microbiology (14) 14
branching ratio: ratio: measured (13) 13
epidemiology (13) 13
flavor physics (13) 13
health aspects (13) 13
medicine, general & internal (13) 13
multidisciplinary sciences (13) 13
research article (13) 13
treatment outcome (13) 13
13000 gev-cms (12) 12
cardiac & cardiovascular systems (12) 12
clinical trials (12) 12
nuclear and particle physics. atomic energy. radioactivity (12) 12
oxidative stress (12) 12
pharmacology & pharmacy (12) 12
phenomenology (12) 12
physics, multidisciplinary (12) 12
physics, particles & fields (12) 12
decay (11) 11
medicine, research & experimental (11) 11
prevalence (11) 11
prevention (11) 11
rapidity dependence (11) 11
rats, wistar (11) 11
science (11) 11
spain (11) 11
studies (11) 11
adolescent (10) 10
aged, 80 and over (10) 10
cp violation (10) 10
expression (10) 10
hypertension (10) 10
physiological aspects (10) 10
radiation therapy (10) 10
therapy (10) 10
tool (10) 10
b0: hadronic decay (9) 9
clinical neurology (9) 9
dose-response relationship, drug (9) 9
double-blind method (9) 9
endothelial dysfunction (9) 9
endothelium, vascular - drug effects (9) 9
glioblastoma (9) 9
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (17) 17
UTL at Downsview - May be requested (7) 7
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
Earth Sciences (Noranda) - Stacks (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Online Resources - Online (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
UofT at Mississauga - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
Victoria University CRRS - Library use only (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (404) 404
Spanish (169) 169
Portuguese (29) 29
French (4) 4
Latin (4) 4
German (2) 2
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Study of tumor infiltrating immune CELLS and vasculature in human gliomas: Differences in IDH1/2 mutant versus IDH1/2WT tumors
by Martin Soberón, Maria Cruz and Sepulveda Sanchez, Juan Manuel Manuel and Gargini, Ricardo and Segura, Berta and Gutierrez, Jacquelin and Ruano, Yolanda and Cantero, Diana and Hernandez-Lain, Aurelio and Sanchez-Gomez, Pilar and Perez-Núñez, Angel and Jimenez Roldan, Luis and Marín, Patricia and Castellano, Daniel E and De Velasco, Guillermo and Cejalvo, Teresa
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. 2030 - 2030
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Combination of statin/vitamin D and metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of two randomized clinical trials
by de Velasco, Guillermo and Lora, David and Carretero-Gonzalez, Alberto and Martin Soberón, Maria Cruz and Sepulveda Sanchez, Juan Manuel Manuel and Lorente, David and Castellano, Daniel E
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. 6617 - 6617
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
by Weller, Michael and Butowski, Nicholas and Tran, David D and Recht, Lawrence and Recht, Lawrence D and Lim, Michael and Hirte, Hal and Ashby, Lynn and Mechtler, Laszlo and Goldlust, Samuel and Goldlust, Samuel A and Iwamoto, Fabio and Drappatz, Jan and O'Rourke, James and O'Rourke, Donald M and Wong, Mark and Hamilton, Mark G and Hamilton, Mark and Finocchiaro, Gaetano and Perry, James and Wick, Wolfgang and Green, Jennifer and He, Yi and Turner, Christopher D and Yellin, Michael J and Keler, Tibor and Davis, Thomas A and Stupp, Roger and Sampson, John H and Campian, Jian and Becker, Kevin and Barnett, Gene and Nicholas, Garth and Desjardins, Annick and Benkers, Tara and Wagle, Naveed and Groves, Morris and Kesari, Santosh and Horvath, Zsolt and Merrell, Ryan and Curry, Richard and Schuster, David and Mrugala, Maciej and Jensen, Randy and Trusheim, John and Lesser, Glenn and Belanger, Karl and Sloan, Andrew and Purow, Benjamin and Fink, Karen and Raizer, Jeffrey and Schulder, Michael and Nair, Suresh and Peak, Scott and Brandes, Alba and Mohile, Nimish and Landolfi, Joseph and Olson, Jon and Jennens, Ross and DeSouza, Paul and Robinson, Bridget and Crittenden, Marka and Shih, Kent and Flowers, Alexandra and Ong, Shirley and Connelly, Jennifer and Hadjipanayis, Costas and Giglio, Pierre and Mott, Frank and Mathieu, David and Lessard, Nathalie and Sepulveda, Sanchez Juan and Lövey, József and Wheeler, Helen and Inglis, Po-Ling and Hardie, Claire and Bota, Daniela and Lesniak, Maciej and Portnow, Jana and Frankel, Bruce and Junck, Larry and Thompson, Reid and Berk, Lawrence and McGhie, John and Macdonald, David and Saran, Frank and Soffietti, Riccardo and Blumenthal, Deborah and André de, Sá Barreto Costa Marcos and Nowak, Anna and Singhal, Nimit and Hottinger, Andreas and Schmid, Andrea and Srkalovic, Gordan and Baskin, David and Fadul, Camilo and Nabors, Louis and LaRocca, Renato and Villano, John and Paleologos, Nina and ... and ACT IV Trial Investigators and ACT IV trial investigators
The Lancet Oncology, ISSN 1470-2045, 10/2017, Volume 18, Issue 10, pp. 1373 - 1385
Rindopepimut (also known as CDX-110), a vaccine targeting the deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet... 
GLIOMAS | ONCOLOGY | RECURSIVE PARTITIONING ANALYSIS | GROWTH-FACTOR | RADIOTHERAPY | CANCER | PEPTIDE | ADJUVANT TEMOZOLOMIDE | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Brain Neoplasms - pathology | ErbB Receptors - genetics | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Patient Selection | Dose-Response Relationship, Drug | Young Adult | Glioblastoma - genetics | Time Factors | Dacarbazine - analogs & derivatives | Adult | Female | Vaccines, Subunit - adverse effects | Brain Neoplasms - mortality | Dacarbazine - administration & dosage | Double-Blind Method | Drug Administration Schedule | Cancer Vaccines - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Neoplasms - genetics | Cancer Vaccines - adverse effects | Treatment Outcome | Brain Neoplasms - drug therapy | Disease-Free Survival | Internationality | Vaccines, Subunit - administration & dosage | Glioblastoma - pathology | Survival Analysis | Aged | Temozolomide | Glioblastoma - drug therapy | Glioblastoma - mortality | Antimitotic agents | Clinical trials | Care and treatment | Product development | Antineoplastic agents | Glioblastoma multiforme | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Comunicación
: convergencia digital y medios de comunicación
by Granat Ramos, María Mirna and Sepúlveda García, Lucinda and Garza Sánchez, Juan Antonio
2012, 1. ed., Tendencias, ISBN 6074339198, 341
Social aspects | Digital media | Digital communications
Book
Details down arrow
5. Full Text Abstract 3826: Brevican absence and YKL-40 over-expression are associated to the mesenchymal profile and in vitro 3D-neurosphere growth of human glioma
by Martinez, Paloma Fernandez and Casans, Cristina Zahonero and de la Rosa, Natividad Pozo and Ayuso, Angel and de Sola, Rafael Garcia and Sanchez, Juan Manuel Sepulveda and Gomez, Pilar Sanchez
Cancer Research, ISSN 0008-5472, 04/2011, Volume 71, Issue 8 Supplement, pp. 3826 - 3826
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Phase II trial of palbociclib in recurrent RB-positive anaplastic oligodendroglioma: A Spanish group for research in neurooncology (GEINO) trial
by Sepulveda-Sanchez, Juan Manuel and Gil Gil, Miguel J and Alonso, Miriam and Vaz Salgado, María Ángeles and Vicente, Elena and Mesia Barroso, Carlos and Rodriguez Sanchez, Angel and Durán, Gema and De Las Penas, Ramon and Muñoz-Langa, José and de Velasco, Guillermo and Hernandez-Lain, Aurelio and Hilario, Amaya and Navarro, L Miguel and Benavides, Manuel and Oleaga, Laura and Cantero, Diana and Ruano, Yolanda and Sanchez-Gomez, Pilar and Pineda, Estela
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. 2038 - 2038
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma
by Brandes, Alba A and Carpentier, Antoine F and Kesari, Santosh and Sepulveda-Sanchez, Juan M and Wheeler, Helen R and Chinot, Olivier and Cher, Lawrence and Steinbach, Joachim P and Capper, David and Specenier, Pol and Rodon, Jordi and Cleverly, Ann and Smith, Claire and Gueorguieva, Ivelina and Miles, Colin and Guba, Susan C and Desaiah, Durisala and Lahn, Michael M and Wick, Wolfgang
Neuro-Oncology, ISSN 1522-8517, 08/2016, Volume 18, Issue 8, pp. 1146 - 1156
The combination of galunisertib, a transforming growth factor (TGF)-beta receptor (R)1 kinase inhibitor, and lomustine was found to have antitumor activity in... 
Antitumor activity | Galunisertib monohydrate (LY2157299) | Bayesian design | Safety | Pharmacokinetics | Phase II randomized study | SURVIVAL | CELLS | DIAGNOSIS | TGF-BETA | KINASE INHIBITOR | CLINICAL NEUROLOGY | INHIBITOR LY2157299 MONOHYDRATE | ONCOLOGY | antitumor activity | safety | GROWTH | pharmacokinetics | galunisertib monohydrate (LY2157299) | ASSOCIATION | Pyrazoles - therapeutic use | Humans | Lomustine - adverse effects | Middle Aged | Kaplan-Meier Estimate | Male | Treatment Outcome | Brain Neoplasms - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Quinolines - pharmacokinetics | Disease-Free Survival | Drug Therapy, Combination - adverse effects | Drug Therapy, Combination - methods | Lomustine - pharmacokinetics | Female | Lomustine - therapeutic use | Quinolines - therapeutic use | Antineoplastic Agents, Alkylating - adverse effects | Glioblastoma - drug therapy | Pyrazoles - pharmacokinetics | Quinolines - adverse effects | Pyrazoles - adverse effects | Clinical Investigations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Circulating endothelial cells: Prognostic value in patients with glioblastoma
by Vaz Salgado, María Ángeles and Earl, Julie and Berrocal, Victor Rodriguez and Salge, Freddy and Gomez, Ana and Corral de la Fuente, Elena and Sepulveda Sanchez, Juan Manuel Manuel and Perez-Núñez, Angel and Muriel, Alfonso and Lourido, Daniel and Carrato, Alfredo and Ley, Luis
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. e13517 - e13517
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Phase I study of CC-90010 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
by Moreno, Victor and Braña, Irene and Sepulveda Sanchez, Juan Manuel Manuel and Villar, Maria Vieito and Hernandez-Guerrero, Tatiana and Doger, Bernard and Saavedra, Omar and Ferrero, Olga and Sarmiento, Rafael and Arias, Marina and De Alvaro, Juan and DiMartino, Jorge F and Zuraek, Marlene and Sánchez Pérez, Tania and Filvaroff, Ellen and Aronchik, Ida and Lamba, Manisha and Hanna, Bishoy and Nikolova, Zariana G
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. 3015 - 3015
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Intravitreal bevacizumab (Avastin®) for diabetic retinopathy at 24-months: The 2008 Juan Verdaguer-planas lecture
by Arevalo, J. Fernando and Arevalo, J Fernando and Sanchez, Juan G and Sanchez, Juan G and Lasave, Andres F and Lasave, Andres F and Wu, Lihteh and Wu, Lihteh and Maia, Mauricio and Maia, Mauricio and Bonafonte, Sergio and Bonafonte, Sergio and Brito, Miguel and Brito, Miguel and Alezzandrini, Arturo A and Alezzandrini, Arturo A and Restrepo, Natalia and Restrepo, Natalia and Berrocal, Maria H and Berrocal, Maria H and Saravia, Mario and Saravia, Mario and Farah, Michel Eid and Farah, Michel E and Fromow-Guerra, Jans and Fromow-Guerra, Jans and Morales-Canton, Virgilio and Morales-Canton, Virgilio and Wu, L and Pan-American Collaborative Retina Study Group (PACORES), Collaborative Retina Study Group (PACORES) and Espinoza, J.V and Maia, M and Aggio, F.B and Quiroz-Mercado, H and Guerrero-Naranjo, J.L and Rodriguez, F.J and Infante, R and Medina, D and Cruz-Villegas, V and Graue-Wiechers, F and Lozano-Rechy, D and Robledo, V and Rodriguez-Loaiza, J.L and Roca, J.A and Reategui, G and Saravia, Mario J and Martinez-Cartier, M and Avila, M and Cardillo, J and Costa, R.A and Verdaguer, J and Carpentier, C and Verdaguer, J.I and Filsecker, D.L and Sepúlveda, G and Sanchez, F and Marini, C and Garcia, B
Current diabetes reviews, ISSN 1573-3998, 2010, Volume 6, Issue 5, pp. 313 - 322
Intravitreal bevacizumab | Diffuse diabetic macular edema | Tractional retinal detachment | Panretinal photocoagulation | Proliferative diabetic retinopathy | Vascular endothelial growth factor
Journal Article
Details down arrow
11. Full Text Randomized phase IIb clinical trial of continuation or non-continuation with six cycles of temozolomide after the first six cycles of standard first-line treatment in patients with glioblastoma: A Spanish research group in neuro-oncology (GEINO) trial
by Balana, Carmen and Mesia Barroso, Carlos and Berron, Sonia Del Barco and Pineda Losada, Estela and Muñoz-Langa, José and Estival, Anna and De las Peñas, Ramon and Fuster, Jose and Gil Gil, Miguel J and Navarro, L Miguel and Alonso, Miriam and Herrero, Ana and Vaz Salgado, María Ángeles and Peralta, Sergi and Olier, Clara and Pérez-Segura, Pedro and Covela Rúa, Marta and Carrato, Cristina and Sanz, Carolina and Sepulveda-Sanchez, Juan Manuel
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. 2001 - 2001
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Biomarker and histopathology evaluation of patients with recurrent glioblastoma treated with galunisertib, lomustine, or the combination of galunisertib and lomustine
by Capper, David and von Deimling, Andreas and Brandes, Alba A and Carpentier, Antoine F and Kesari, Santosh and Sepulveda-Sanchez, Juan M and Wheeler, Helen R and Chinot, Olivier and Cher, Lawrence and Steinbach, Joachim P and Specenier, Pol and Rodon, Jordi and Cleverly, Ann and Smith, Claire and Gueorguieva, Ivelina and Miles, Colin and Guba, Susan C and Desaiah, Durisala and Estrem, Shawn T and Lahn, Michael M and Wick, Wolfgang
International Journal of Molecular Sciences, ISSN 1661-6596, 05/2017, Volume 18, Issue 5, p. 995
Galunisertib, a Transforming growth factor-beta RI (TGF-beta RI) kinase inhibitor, blocks TGF-beta-mediated tumor growth in glioblastoma. In a three-arm study... 
Biomarkers | pSMAD2 | TGF-β | Galunisertib monohydrate (LY2157299) | CDK4/CDK6 | SURVIVAL | IMMUNE CELLS | biomarkers | BIOCHEMISTRY & MOLECULAR BIOLOGY | PHASE-II | CANCER | CHEMISTRY, MULTIDISCIPLINARY | TUMOR-INFILTRATING LYMPHOCYTES | TGF-beta | galunisertib monohydrate (LY2157299) | RADIOTHERAPY | Pyrazoles - therapeutic use | Humans | Lomustine - adverse effects | Neoplasm Recurrence, Local - drug therapy | Male | Quinolines - administration & dosage | Neoplasm Recurrence, Local - pathology | CD4-CD8 Ratio | Forkhead Transcription Factors - metabolism | Biomarkers, Tumor - metabolism | Adult | Female | Lomustine - therapeutic use | Neoplasm Recurrence, Local - blood | Cytokines - blood | Pyrazoles - adverse effects | Glioblastoma - blood | Smad2 Protein - metabolism | Antineoplastic Combined Chemotherapy Protocols | Biomarkers, Tumor - blood | Pyrazoles - administration & dosage | Forkhead Transcription Factors - blood | Glioblastoma - pathology | Survival Analysis | Isocitrate Dehydrogenase - metabolism | Quinolines - therapeutic use | Glioblastoma - drug therapy | Lomustine - administration & dosage | Quinolines - adverse effects | Therapy | CD8 antigen | Glioblastoma | Transforming growth factor-a | Lymphocytes T | Dehydrogenase | Kinases | Macrophages | CCL22 protein | Alterations | Macrophage-derived chemokine | Histopathology | Lymphocytes | Foxp3 protein | Isocitrate dehydrogenase | Dosing | Leukocytes (eosinophilic) | Glial fibrillary acidic protein | Markers | Pharmacology | CD3 antigen | Assessments | Patients | Survival | CD4 antigen | Pathology | Inhibitors | Chemokines | Cytoplasm | Plasmas (physics) | Eosinophils | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text [beta]1-subunit--induced structural rearrangements of the [Ca.sup.2+]- and voltage-activated [K.sup.+] channel
by Castillo, Juan P and Sanchez-Rodriguez, Jorge E and Hyde, H. Clark and Zaelzer, Cristian A and Aguayo, Daniel and Sepulveda, Romina V and Luk, Louis Y.P and Kent, Stephen B.H and Gonzalez-Nilo, Fernando D and Bezanilla, Francisco and Latorre, Ramon
Proceedings of the National Academy of Sciences of the United States, ISSN 0027-8424, 06/2016, Volume 113, Issue 23, p. E3231
Large-conductance [Ca.sup.2+]- and voltage-activated [K.sup.+] (BK) channels are involved in a large variety of physiological processes. Regulatory... 
Electrophysiology | Calcium channels | Potassium channels | Observations | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. beta 1-subunit-induced structural rearrangements of the Ca super( 2+)- and voltage-activated K+ (BK) channel
by Castillo, Juan P and Sanchez-Rodriguez, Jorge E and Hyde, H Clark and Zaelzer, Cristian A and Aguayo, Daniel and Sepulveda, Romina V and Luk, Louis YP and Kent, Stephen BH and Gonzalez-Nilo, Fernando D and Bezanilla, Francisco and Latorre, Ramon
Proceedings of the National Academy of Sciences, USA, ISSN 0027-8424, 06/2016, Volume 113, Issue 23, pp. E3231 - E3231
Large-conductance Ca super( 2+)- and voltage-activated K super( +) (BK) channels are involved in a large variety of physiological processes. Regulatory beta... 
Journal Article
Details down arrow
15. Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor‑β receptor I kinase inhibitor LY2157299 monohydrate
by Sepulveda-Sanchez, Juan and Ramos, Ana and Hilario, Amaya and De Velasco, Guillermo and Castellano, Daniel and De La Torre, Marta Garcia and Rodon, Jordi and Lahn, Michael F
Oncology Letters, ISSN 1792-1074, 2015, Volume 9, Issue 6, pp. 2442 - 2448
Transforming growth factor-beta (TGF-beta) signaling is associated with tumor progression and vascularization in malignant glioma. In the present study,... 
Lomustine | Transforming growth factor‑β inhibitor LY2157299 | Magnetic resonance imaging | Combination therapy | Glioblastoma | magnetic resonance imaging | CEREBRAL BLOOD-VOLUME | RESPONSE CRITERIA | ANGIOGENESIS | BEVACIZUMAB | PHASE-II | INDUCTION | lomustine | MALIGNANT GLIOMA | glioblastoma | ONCOLOGY | transforming growth factor-beta inhibitor LY2157299 | combination therapy | GRADE | IRINOTECAN | TUMOR-GROWTH
Journal Article
Details down arrow
16. Full Text First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma
by Rodon, Jordi and Carducci, Michael A and Sepulveda-Sánchez, Juan M and Azaro, Analia and Calvo, Emiliano and Seoane, Joan and Braña, Irene and Sicart, Elisabet and Gueorguieva, Ivelina and Cleverly, Ann L and Pillay, N. Sokalingum and Desaiah, Durisala and Estrem, Shawn T and Paz-Ares, Luis and Holdhoff, Matthias and Blakeley, Jaishri and Lahn, Michael M and Baselga, Jose
Clinical Cancer Research, ISSN 1078-0432, 02/2015, Volume 21, Issue 3, pp. 553 - 560
Purpose: TGF beta signaling plays a key role in tumor progression, including malignant glioma. Small-molecule inhibitors such as LY2157299 monohydrate... 
CELLS | INDUCTION | ONCOLOGY | INTEGRATED GENOMIC ANALYSIS | Pyrazoles - therapeutic use | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Quinolines - pharmacology | Young Adult | Neoplasm Grading | Glioma - pathology | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Adult | Female | Antineoplastic Agents - pharmacology | Pyrazoles - pharmacology | Treatment Outcome | Neoplasms - drug therapy | Magnetic Resonance Imaging | Receptors, Transforming Growth Factor beta - antagonists & inhibitors | Protein Kinase Inhibitors - therapeutic use | Aged | Protein Kinase Inhibitors - pharmacology | Quinolines - therapeutic use | Neoplasm Staging | Neoplasms - pathology | Glioma - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. El receptor del factor de crecimiento epidérmico (EGFR) en el glioblastoma: Mecanismo de tumorigénesis y papel como diana terapéutica
by Zahonero, Cristina and Sepúlveda, Juan M and Sánchez-Gómez, Pilar
Revista de Neurologia, ISSN 0210-0010, 07/2015, Volume 61, Issue 2, pp. 85 - 93
EGFRvIII | Anti-EGFR treatment | Resistance to therapy | Signalling | EGFR | Glioblastoma
Journal Article
Details down arrow
18. Full Text Ocoxin Modulates Cancer Stem Cells and M2 Macrophage Polarization in Glioblastoma
by Hernandez-SanMiguel, E and Gargini, R and Cejalvo, T and Segura-Collar, B and Nunez-Hervada, P and Hortiguela, R and Sepulveda-Sanchez, JM and Hernandez-Lain, A and Perez-Nunez, A and Sanz, E and Sanchez-Gomez, P
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, ISSN 1942-0900, 08/2019, Volume 2019, pp. 9719730 - 12
Glioblastoma (GBM) is the most common and devastating primary brain tumor. The presence of cancer stem cells (CSCs) has been linked to their therapy... 
OXIDATIVE STRESS | ACTIVATION | INHIBITION | COLORECTAL-CANCER | PHENOTYPE | DIFFERENTIATION | ORAL SOLUTION | TUMORS | PROGRESSION | EGFR | CELL BIOLOGY | Antioxidants | Ethylenediaminetetraacetic acid | Medical equipment and supplies industry | Medical test kit industry | Brain tumors | Stem cells | Dietary supplements | Transplantation | Macrophages | Glioblastoma multiforme | Cancer | Oxidative stress | Medical research | Medical prognosis | Brain cancer | Penicillin | Cancer therapies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification
by Sepúlveda-Sánchez, Juan Manuel and Vaz, María Ángeles and Balañá, Carmen and Gil-Gil, Miguel and Reynés, Gaspar and Gallego, Óscar and Martínez-García, María and Vicente, Elena and Quindós, María and Luque, Raquel and Ramos, Ana and Ruano, Yolanda and Pérez-Segura, Pedro and Benavides, Manuel and Sánchez-Gómez, Pilar and Hernández-Laín, Aurelio
Neuro-Oncology, ISSN 1522-8517, 11/2017, Volume 19, Issue 11, pp. 1522 - 1531
Background. We conducted a multicenter, 2-stage, open-label, phase II trial to assess the efficacy and safety of dacomitinib in adult patients with recurrent... 
Dacomitinib | High-grade glioma | EGFR | Glioblastoma | GEFITINIB | dacomitinib | OPEN-LABEL | CLINICAL NEUROLOGY | TEMOZOLOMIDE | CELL LUNG-CANCER | HETEROGENEITY | GROWTH-FACTOR RECEPTOR | ERBB INHIBITOR | glioblastoma | ONCOLOGY | PATHWAY | high-grade glioma | HIGH-GRADE GLIOMAS | ERLOTINIB | Clinical Investigations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text 468 HOW DO GENETIC POLYMORPHISMS INFLUENCE IN SUNITINIB TREATED METASTATIC RENAL CARCINOMA?: A PROSPECTIVE OBSERVATIONAL STUDY AND VALIDATION
by Villacampa Aubá, Felipe and Guerrero Ramos, Félix and Díez Sicilia, Laura and García Gómez, Borja and Sepúlveda Sánchez, Juan Manuel and Ospina Galeano, Irma Amparo and Garc ía González, Luc ía and Jiménez Alcaide, Estíbaliz and Duarte Ojeda, José Manuel and de la Rosa Kehrman, Federico and Castellano Gauna, Daniel and Díaz González, Rafael
Journal of Urology, The, ISSN 0022-5347, 2013, Volume 189, Issue 4, pp. e192 - e193
Urology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.